Halocarbon appoints David Bacon as Chief Executive

His top priorities will be leading the next phase of the company’s growth and product innovation

Halocarbon Products, a worldwide producer of speciality fluorochemicals and inhalation anaesthetics, has announced that David Bacon will be joining the company as Chief Executive on 28 April.

Bacon comes to Halocarbon with more than 24 years of experience in market analysis and driving innovation. As CEO of Halocarbon, Bacon’s top priorities will be leading the next phase of the company’s growth and product innovation.

Most recently, Bacon was President of LSP Products Group. Prior to this he was General Manager for the AT Plastics business at Celanese. He has also worked as a management consultant for McKinsey & Company.

Bacon began his professional career at Exxon, where held roles of increasing responsibility in process and refinery engineering.

You may also like

Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Ingredients

Rousselot announces access to pure gelatins through BIO INX

Research and technical grade gelatins are now available for online purchase in Canada, Europe, South Korea and the US
Manufacturing

Exploring TiO2-free hard capsules

The quest for TiO2 alternatives underscores the unwavering commitment of the pharmaceutical industry to deliver safe and effective medicines to patients worldwide
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Subscribe now